Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials. - Wikidata - wikimedia - TriplyDB

Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials.

Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials.

http://www.wikidata.org/entity/Q37324869

about

Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII.Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).Survival of adolescents with cancer treated at pediatric versus adult oncology treatment centers in France.Comparison of survival of adolescents and young adults with hematologic malignancies in Osaka, Japan.Acute Myeloid Leukemia in Adolescents and Young Adults Treated in Pediatric and Adult Departments in the Nordic Countries.Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols.Adolescents and Young Adults with Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia: Impact of Care at Specialized Cancer Centers on Survival Outcome.Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia.Acute myelogenous leukemia in adolescents and young adults.Sex disparity in childhood and young adult acute myeloid leukemia (AML) survival: Evidence from US population data.

P2860

Q26799609-F6E944AD-C597-4537-BBFE-F939225DDF5C Q33434223-4B961055-E04E-46B9-A1F9-5EE4AD5B5087 Q36739522-3F767AF8-EC8B-41AE-8CC5-66194925EACE Q39176628-0E421A17-38DF-4CB8-AC1D-451F2534F9A5 Q40179856-01B21643-7E4A-4F91-B518-395052828701 Q40634949-9B84B695-1198-44F2-8FFE-DD5519813522 Q40781300-443F097B-1D82-4993-A24F-0CA0DC571ABB Q46143417-F733C3DE-C96D-48C7-BE46-B76F1E715DAB Q47805959-CA4AEB91-67E9-4DFD-AF7A-85273F2E24CC Q52318200-3A1C9D42-57FB-4772-A71F-71B07861DBC0 Q55163802-CF65ABD1-8A15-449E-A657-BFA148CF916C

P2860

Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials.

http://www.wikidata.org/entity/Q37324869

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Outcome of adolescents and you ...... ared to CALGB and SWOG trials.

@en

Outcome of adolescents and you ...... ared to CALGB and SWOG trials.

@nl

type

label

Outcome of adolescents and you ...... ared to CALGB and SWOG trials.

@en

Outcome of adolescents and you ...... ared to CALGB and SWOG trials.

@nl

prefLabel

Outcome of adolescents and you ...... ared to CALGB and SWOG trials.

@en

Outcome of adolescents and you ...... ared to CALGB and SWOG trials.

@nl

P1433

Q37324869-E7324971-C16A-4A8F-938B-CC9445FD9CE3

P1476

Q37324869-2643F016-BBBF-4D91-94C6-9529C69C4FB6

P2093

Q37324869-2C0D61D6-AC0E-4CD6-9998-5F807CEB2EF2

Q37324869-3CFF74F3-D13F-444D-BA40-E31F64BBEA3A

Q37324869-3E970ADE-A667-4CDA-9A23-5DDF610C0928

Q37324869-4B30A6CE-79E4-47E4-B1BC-94D4218C00F7

Q37324869-B5038DF5-B160-4599-A5DD-DEDD986899B7

Q37324869-C3400ADB-8DC4-4C66-8683-AEDE20B3A795

Q37324869-D083882B-4DA6-44E7-8905-6561C31FE80E

Q37324869-E5C1E4CD-A3DB-425A-83F0-BC8E7DB9D949

P2860

Q37324869-00C48567-7A27-49ED-A5A9-7A4A35AA0371

Q37324869-215531F6-C01F-4694-B167-EDDAD61A774C

Q37324869-2C723322-2188-445A-B1F0-BCD1FBEF5F19

Q37324869-2CB45810-BB44-4A8D-8513-8A839351FB40

Q37324869-31E0DB55-4AAF-44D7-97A7-0951F4D57E1B

Q37324869-3932488B-0D4F-4516-9694-7825D308C456

Q37324869-5BF82552-6BF8-4DC0-8669-27D1CE0225AC

Q37324869-62A08BD0-DF6E-4BCE-964E-3CF36360CADB

Q37324869-6AF2BACF-2021-4005-B45D-C79006F741D5

Q37324869-6BB43813-0B19-4255-852D-101BE39DC43A

P304

Q37324869-DEEC9E01-233B-422F-9F3C-0D4038787A1B

P31

Q37324869-2cd9d60b-6168-4b71-8876-4087a033c2b5

Q37324869-DC0CEDBD-32C7-4F5A-BA45-BEB4E693D3DC

P356

Q37324869-EE98B2E3-AB96-4BA2-A323-A234CE1280D0

P407

Q37324869-951231EB-7081-4E2C-84FC-92EE2CBE8F56

P433

Q37324869-5D79D364-4C1D-48AC-9A7F-79AA80561180

P478

Q37324869-8D687E34-5C8F-495F-9BE5-9201F8CA681A

P50

Q37324869-0CC432D7-2045-478F-A2D0-00D6C5BB2957

Q37324869-85768119-0606-40B2-A701-8EFA344E6E02

Q37324869-929E970C-12F3-46F3-BEFB-EC3659A0C425

P577

Q37324869-D86DDBBB-626E-4C6E-8EF0-4067D23662C0

P698

Q37324869-32D014A0-0FBD-41D8-B61F-89BF47201C9B

P921

Q37324869-A388E9A1-6C2C-4575-A146-45A1561C3AA3

Q37324869-BCA49475-DBA0-4D3E-9F14-1CA1CCEEDB03

P932

Q37324869-D8ADDF42-8547-47D3-84B3-6D013D4C53AB

P356

P1433

P1476

Outcome of adolescents and you ...... ared to CALGB and SWOG trials.

@en

P2093

Anna R K Franklin

http://www.w3.org/2001/XMLSchema#string

Elihu H Estey

http://www.w3.org/2001/XMLSchema#string

John Horan

http://www.w3.org/2001/XMLSchema#string

Kathleen A Donohue

http://www.w3.org/2001/XMLSchema#string

Richard A Larson

http://www.w3.org/2001/XMLSchema#string

Robert B Gerbing

http://www.w3.org/2001/XMLSchema#string

Todd A Alonzo

http://www.w3.org/2001/XMLSchema#string

William G Woods

http://www.w3.org/2001/XMLSchema#string

P2860

A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Part

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study

Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022.

Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study.

P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808

Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution.

Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children's Oncology Group.

Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.

P304

4170-4179

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.28344

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

Clara D. Bloomfield

Frederick R. Appelbaum

P577

2013-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24104597

http://www.w3.org/2001/XMLSchema#string

P921

P932

3833872

http://www.w3.org/2001/XMLSchema#string